These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 36207324)

  • 21. Immunogenicity and efficacy of          heterologous ChAdOx1-BNT162b2 vaccination.
    Pozzetto B; Legros V; Djebali S; Barateau V; Guibert N; Villard M; Peyrot L; Allatif O; Fassier JB; Massardier-Pilonchéry A; Brengel-Pesce K; Yaugel-Novoa M; Denolly S; Boson B; Bourlet T; Bal A; Valette M; Andrieu T; Lina B; ; Cosset FL; Paul S; Defrance T; Marvel J; Walzer T; Trouillet-Assant S
    Nature; 2021 Dec; 600(7890):701-706. PubMed ID: 34673755
    [TBL] [Abstract][Full Text] [Related]  

  • 22. COVID-19 vaccine waning and effectiveness and side-effects of boosters: a prospective community study from the ZOE COVID Study.
    Menni C; May A; Polidori L; Louca P; Wolf J; Capdevila J; Hu C; Ourselin S; Steves CJ; Valdes AM; Spector TD
    Lancet Infect Dis; 2022 Jul; 22(7):1002-1010. PubMed ID: 35405090
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of immune activation of the COVID vaccines: ChAdOx1, BNT162b2, mRNA-1273, BBIBP-CorV, and Gam-COVID-Vac from serological human samples in Hungary showed higher protection after mRNA-based immunization.
    Fodor E; Olmos Calvo I; Kuten-Pella O; Hamar E; Bukva M; Madár Á; Hornyák I; Hinsenkamp A; Hetényi R; Földes F; Brigitta Z; Jakab F; Kemenesi G; Lacza Z
    Eur Rev Med Pharmacol Sci; 2022 Jul; 26(14):5297-5306. PubMed ID: 35916830
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Humoral immune response after different SARS-CoV-2 vaccination regimens.
    Rose R; Neumann F; Grobe O; Lorentz T; Fickenscher H; Krumbholz A
    BMC Med; 2022 Jan; 20(1):31. PubMed ID: 35057798
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lung Transplant Recipients Immunogenicity after Heterologous ChAdOx1 nCoV-19-BNT162b2 mRNA Vaccination.
    Catry E; Favresse J; Gillot C; Bayart JL; Frérotte D; Dumonceaux M; Evrard P; Mullier F; Douxfils J; Carlier FM; Closset M
    Viruses; 2022 Jul; 14(7):. PubMed ID: 35891450
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Outcome of BNT162b2, ChAdOx1-Sand mRNA-1273 Vaccines and Two Boosters: A Prospective Longitudinal Real-World Study.
    Kamal SM; Naghib MM; Daadour M; Alsuliman MN; Alanazi ZG; Basalem AA; Alaskar AM; Saed K
    Viruses; 2023 Jan; 15(2):. PubMed ID: 36851540
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dynamics of SARS-CoV-2 Spike-IgG throughout Three COVID-19 Vaccination Regimens: A 21-Month Longitudinal Study of 82 Norwegian Healthcare Workers.
    Augustinussen MH; Tylden GD; Rinaldo CH
    Viruses; 2023 Feb; 15(3):. PubMed ID: 36992328
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antibody responses after a single dose of ChAdOx1 nCoV-19 vaccine in healthcare workers previously infected with SARS-CoV-2.
    Havervall S; Marking U; Greilert-Norin N; Ng H; Gordon M; Salomonsson AC; Hellström C; Pin E; Blom K; Mangsbo S; Phillipson M; Klingström J; Hober S; Nilsson P; Åberg M; Thålin C
    EBioMedicine; 2021 Aug; 70():103523. PubMed ID: 34391088
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of Cellular Responses to ChAdOx1-nCoV-19 and BNT162b2 Vaccinations.
    Lee TH; Nam M; Seo JD; Kim H; Kim HR; Hur M; Yun YM; Moon HW
    Ann Lab Med; 2023 May; 43(3):290-294. PubMed ID: 36544341
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reactogenicity among health care workers following a BNT162b2 or mRNA-1273 second dose after priming with a ChAdOx1 nCOV-19 vaccine.
    Baldolli A; Fournier A; Verdon R; Michon J
    Clin Microbiol Infect; 2022 Jun; 28(6):885.e1-885.e5. PubMed ID: 35182759
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Kinetics of the Antibody Response to Boostering With Three Different Vaccines Against SARS-CoV-2.
    Markewitz R; Juhl D; Pauli D; Görg S; Junker R; Rupp J; Engel S; Steinhagen K; Herbst V; Zapf D; Krüger C; Brockmann C; Leypoldt F; Dargvainiene J; Schomburg B; Sharifzadeh S; Nejad LS; Wandinger KP; Ziemann M
    Front Immunol; 2022; 13():811020. PubMed ID: 35126395
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety of heterologous primary and booster schedules with ChAdOx1-S and BNT162b2 or mRNA-1273 vaccines: nationwide cohort study.
    Andersson NW; Thiesson EM; Laursen MV; Mogensen SH; Kjær J; Hviid A
    BMJ; 2022 Jul; 378():e070483. PubMed ID: 35831006
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety and immunogenicity of concomitant administration of COVID-19 vaccines (ChAdOx1 or BNT162b2) with seasonal influenza vaccines in adults in the UK (ComFluCOV): a multicentre, randomised, controlled, phase 4 trial.
    Lazarus R; Baos S; Cappel-Porter H; Carson-Stevens A; Clout M; Culliford L; Emmett SR; Garstang J; Gbadamoshi L; Hallis B; Harris RA; Hutton D; Jacobsen N; Joyce K; Kaminski R; Libri V; Middleditch A; McCullagh L; Moran E; Phillipson A; Price E; Ryan J; Thirard R; Todd R; Snape MD; Tucker D; Williams RL; Nguyen-Van-Tam JS; Finn A; Rogers CA;
    Lancet; 2021 Dec; 398(10318):2277-2287. PubMed ID: 34774197
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Humeral and cellular immune responses to SARS-CoV-2 vaccination in patients on peritoneal dialysis.
    Yu ZY; Lai CF; Lai TS; Yang SY; Chen SI; Lai MJ; Kang CM; Huang YT; Chen YT; Hsueh PR; Chen YM; Lin SL
    J Formos Med Assoc; 2023 Sep; 122(9):922-931. PubMed ID: 36894486
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Protective Duration of ChAdOx1 and BNT162b2 Vaccines Against SARS-CoV-2 Infection.
    Alfaleh A; Alkattan A; Alzaher A; Radwan N; Mahmoud N; Alageel A; Alhabib D; Alsalameen E; Sagor K; Haji A; Alfaifi A; Alabdulkareem K; Ibrahim M
    Clin Drug Investig; 2022 Oct; 42(10):799-806. PubMed ID: 36040662
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Increase over time of antibody levels 3 months after a booster dose as an indication of better protection against Omicron infection.
    Bingula R; Chabrolles H; Bonnet B; Archimbaud C; Brebion A; Cosme J; Ollier A; Dutheil F; Junda M; Mirand A; Regagnon C; Vidal M; Henquell C; Evrard B
    Emerg Microbes Infect; 2023 Dec; 12(1):2184176. PubMed ID: 36848040
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Longevity of immunity following COVID-19 vaccination: a comprehensive review of the currently approved vaccines.
    Jamshidi E; Asgary A; Shafiekhani P; Khajeamiri Y; Mohamed K; Esmaily H; Jamal Rahi S; Mansouri N
    Hum Vaccin Immunother; 2022 Nov; 18(5):2037384. PubMed ID: 35417285
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Heterologous immunization with BNT162b2 followed by mRNA-1273 in dialysis patients: seroconversion and presence of neutralizing antibodies.
    Kohmer N; Rabenau HF; Ciesek S; Krämer BK; Göttmann U; Keller C; Rose D; Blume C; Thomas M; Lammert A; Lammert A
    Nephrol Dial Transplant; 2022 May; 37(6):1132-1139. PubMed ID: 35099023
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Spike-specific humoral and cellular immune responses after COVID-19 mRNA vaccination in patients with cirrhosis: A prospective single center study.
    Iavarone M; Tosetti G; Facchetti F; Topa M; Er JM; Hang SK; Licari D; Lombardi A; D'Ambrosio R; Degasperi E; Loglio A; Oggioni C; Perbellini R; Caccia R; Bandera A; Gori A; Ceriotti F; Scudeller L; Bertoletti A; Lampertico P
    Dig Liver Dis; 2023 Feb; 55(2):160-168. PubMed ID: 36266209
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Humoral immunity against SARS-CoV-2 in workers of social health care centers of Castilla y León after vaccination with the BNT162b2 mRNA vaccine from Pfizer/Biontech.].
    Casas Fischer R
    Rev Esp Salud Publica; 2021 Oct; 95():. PubMed ID: 34690347
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.